Currently, CDK4/6 inhibitors have been approved by the FDA for the treatment of advanced-stage hormone-receptor-positive, HER2-negative breast cancer and also show benefits in non-small cell lung cancer, melanoma, and head and neck squamous cell carcinoma (53, 54). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.